Suchergebnisse - "Hanley, Michael J"

PubPharm (10)

1

Response-Based Dosing for Ponatinib : Model-Based Analyses of the Dose-Ranging OPTIC Study

enthalten in: Clinical pharmacology and therapeutics | 2023

von Hanley, M. | Diderichsen, P. | Rich, B. | +5

2

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development

enthalten in: Journal of clinical pharmacology | 2022

von Hanley, M. | Diderichsen, P. | Narasimhan, N. | +3

3

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer : Second Interim Analysis of the Phase III ALTA-1L Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Camidge, D. | Kim, H. | Ahn, M. | +19

CommentIn: J Clin Oncol. 2020 Nov 1;38(31):3581-3583. - PMID 32897826

4

Clinical Pharmacology of Ixazomib : The First Oral Proteasome Inhibitor

enthalten in: Clinical pharmacokinetics | 2019

von Gupta, N. | Hanley, M. | Xia, C. | +3

5

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor : Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

enthalten in: Journal of clinical pharmacology | 2018

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +13

6

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2018

von Hanley, M. | Gupta, N. | Venkatakrishnan, K. | +6

7

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma : Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6

8

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients : Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range

enthalten in: Journal of clinical pharmacology | 2017

von Hanley, M. | Mould, D. | Taylor, T. | +10

9

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma : a phase 1 study

enthalten in: Journal of hematology & oncology | 2015

von Gupta, N. | Goh, Y. | Min, C. | +10

10

Effect of obesity on the pharmacokinetics of drugs in humans

enthalten in: Clinical pharmacokinetics | 2010

von Hanley, M. | Abernethy, D. | Greenblatt, D.

1
[1]